Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Glycopyrronium bromide is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has few to no central effects. It can be administered orally, intravenously, topically, or via inhalation. It is a synthetic quaternary ammonium compound. The cation, which is the active moiety, is called glycopyrronium (INN) or glycopyrrolate (USAN).
Read the full article on WikipediaSevere primary axillary hyperhidrosis Clinical criteria: Patient must have previously failed topical aluminium chloride hexahydrate after one to two months of treatment; OR Patient must be intolerant to topical aluminium chloride treatment, AND The treatment must be the sole PBS-subsidised therapy for this condition.
“Glycopyrronium competitively blocks muscarinic receptors, thus inhibiting cholinergic transmission.”
“0.6–1.2 hours”
Working under the parallel aged-care framework? Aged-care equivalent →